In September, Chengyi Pharmaceutical had a series of happy events. The company's flagship product "Vk1 Injection" successfully won the list of 19 provincial alliance procurement with the highest comprehensive score, and another product "Inosine Injection" was also selected; Ruicheng Biomedical Technology Co., Ltd., a wholly-owned subsidiary located in Nantong, Jiangsu Province, cooperates with Shanghai Ruijin Hospital to develop a drainage kit for the treatment of pancreatic cancer, which has been registered and approved by Jiangsu Food and Drug Administration and will be listed nationwide; Another subsidiary, Fujian Huakang Pharmaceutical Co., Ltd., has obtained approval for the production license of "Glucosamine Hydrochloride API" from the National Drug Administration, which means that this chemical plant, which has undergone several years of transformation, will successfully transform into a pharmaceutical enterprise.
Over the past 20 years since the implementation of the "August 8th Strategy", the output value of Chengyi Pharmaceutical has increased from 110 million yuan to over 700 million yuan, profits have increased from 10 million yuan to 162 million yuan, and taxes have increased from 10 million yuan to 71.66 million yuan. Guided by the "August 8th Strategy", Chengyi Pharmaceutical has gradually achieved remarkable changes in "product innovation, main board listing, and cloud management", striving to build a "Chengyi map" of the life and health industry, Strive to create a research and development highland, manufacturing highland, and digital highland for marine biomedicine in Zhejiang Province.
Born into the sea
Extracting Medicinal Raw Materials from Shrimp and Crab Shells
The predecessor of Chengyi Pharmaceutical was Tongshan Pharmaceutical Factory in Dongtou County, founded in 1966. At that time, it was a small pharmaceutical factory for military family members. In December 1969, at the age of 19, Yan Yiyi entered the factory and was appointed as the director of Tongshan Pharmaceutical Factory by the Dongtou County Party Committee in January 1980. Yan Yiyi implemented the distribution system reform earlier among industrial enterprises in the province, which reversed the three consecutive years of losses from 1977 to 1979. With the support of the county party committee and government, in March 1994, Yan Yiyi boldly launched a "public private" reform for a period of seven years. By 2001, the company's operating income, profits, and taxes were 4.4 times, 20.7 times, and 14.7 times higher than in the past 27 years (1966-1993), respectively, marking the beginning of a period of rapid growth.
Relying on the sea and living towards the sea, island pharmaceutical enterprises have natural resource advantages in developing marine pharmaceuticals. "Yan Yiyi said that in the past 40 years, although the Dongtou area where the enterprise is located has faced disadvantages such as inconvenient transportation, water and electricity shortages, and insufficient talent, the coastal shrimp and crab shell resources in Dongtou are abundant. By utilizing the advantages of raw materials, in recent years, Chengyi Pharmaceutical has developed into the largest pharmaceutical manufacturer of glucosamine hydrochloride raw materials in China. Glucosamine hydrochloride is prepared by hydrolysis of chitin and is often extracted from shrimp and crab shells. Due to its light weight and large volume, it is not convenient for transportation and is usually produced in coastal areas.
In the process of accelerating development, deepening the cultivation of marine medicine has become an important direction for chengyi pharmaceutical industry. The article of the sea has great potential, and the company is constantly enriching the variety of marine pharmaceuticals, "said Yan Yiyi. Currently, the company has a reserve of multiple products mainly focused on marine pharmaceuticals, including deep-sea fish oil, lipid-lowering, blood pressure lowering, and anti-tumor drugs.
At present, Chengyi Pharmaceutical can produce over 70 varieties and nearly a hundred specifications of drugs and health foods. Its main products include glucosamine hydrochloride raw materials and preparations, tolasemide injection and capsules, gastrodin raw materials, ribavirin and azathioprine raw materials, etc. All products have passed national GMP certification, and multiple products have passed certifications from multiple countries and regions such as the US FDA, EU EMEA, Australia TGA, UK MHRA, and Mexico COFEPRIS.
On March 15, 2017, Chengyi Pharmaceutical successfully listed on the main board of the Shanghai Stock Exchange, becoming the "first stock" in the Wenzhou pharmaceutical industry.
Revitalizing enterprises through scientific and technological innovation
Promoting high-quality development of enterprises
Entering the 105 production workshop of Chengyi Pharmaceutical, there are 5 production lines set up in the vast workshop. From the production of drugs to the packaging of capsules, plate making, packaging, packaging, and transportation to the warehouse, all operations are mechanized. The staff are monitoring the machine operation on the side, in order to discover and solve problems in the first time.
A modern enterprise that has achieved such a high degree of automation in a military family pharmacy located on an island without advantages such as transportation, capital, cost, and talent, Yan Yiyi has brought the entrepreneurial spirit of "diligence, rigor, innovation, and dedication" to the extreme. Especially in terms of technological innovation, in addition to personally participating in the research and development of equipment, significant investments have also been made to attract authoritative experts such as domestic academicians to assist Chengyi Pharmaceutical, opening a door for its high-quality development.
In the pharmaceutical industry, the phenomenon of residual liquid from the injection needle sticking to the neck wall of ampoules during the filling process and being carbonized at high temperature is known as "coke head", which causes significant waste in the pharmaceutical production process. In the past few years, the cumulative losses caused by the scorching head of Chengyi Pharmaceutical have exceeded ten million yuan. And this is only the "tip of the iceberg" among more than 6000 pharmaceutical companies nationwide. Yan Yiyi was determined to overcome this difficult problem and found a solution under the guidance of experts, ultimately achieving the "miracle" of continuous production of 10% glucose solution for 2 days without a single burn. As a result, Yan Yiyi also became the first inventor of the patent.
After going public, Chengyi Pharmaceutical will invest about 5% of its annual operating revenue in research and development, which is higher than the industry average in the province. In recent years, their highly efficient diuretic "Tolasemide" developed and produced has been included in the National Torch Plan project; The antiviral drug "ribavirin" won the National Invention Patent Award; The drug substance for treating childhood leukemia "mercaptopurine" and traditional Chinese patent medicines and simple preparations "Danyining Tablet" are the exclusive products in China. The old formula "Danyining Tablet", which enjoys a high reputation in Wenzhou, focuses on the treatment and maintenance of cholecystitis and other biliary diseases among various people. In 2018, five core products including glucosamine hydrochloride capsules were awarded the "Zhejiang Province Excellent Industrial Product Certificate". In August 2020, their 0.75 grams of glucosamine hydrochloride capsules won the first place in the national centralized procurement bidding for the third batch of drugs. Nowadays, Chengyi Pharmaceutical has become the "industry leader" of this product with its "top sales volume in the country".
Yan Yiyi said that Chengyi Pharmaceutical has continuously focused its product research and development direction on new products such as marine drugs, elderly medication, and anti-tumor drugs. It has established the first academician expert workstation in Dongtou, Chengyi Pharmaceutical Big Health Research Institute, and other fields, making scientific research a driving force for the sustainable development of the enterprise.
In June 2018, with the company's marketing center, technology development center, and securities affairs center settling in Shanghai Hongqiao Fuli Center, Chengyi Pharmaceutical took a substantial step from "sea" to Shanghai. After the "Three Centers" settled in Shanghai, Chengyi Pharmaceutical attracted more pharmaceutical commercial companies to join and made greater strides in drug research and development.
Two strong and one big
Striving to create a market value of 10 billion yuan for a century
For the past 20 years, the company has leveraged its advantages in mountain and sea resources, vigorously developed the marine economy, and promoted the development of underdeveloped areas; At the same time, we will accelerate the construction of advanced manufacturing bases. The preparation workshop of the first phase of the company's health industry park will be built to high standards along the path of industrialization and information integration. Currently, we have built an intelligent factory that is informationized, intelligent, digitized, and standardized, leading the way in promoting new industrialization in the province. We have also been rated as a provincial-level cloud benchmark enterprise and a provincial-level digital workshop.
Standing at a new starting point, Chengyi Pharmaceutical has formulated new goals, which will revolve around the three major development directions of "marine medicine, biopharmaceuticals, traditional Chinese medicine, and the big health industry" and the "100 billion market value, 100 year Chengyi" double hundred goals, accelerate mergers and acquisitions, seize strategic heights, empower enterprises with new value, and achieve company collectivization and high-quality development.
At the same time, the company is accelerating the implementation of the "two strong and one large" strategy, strengthening the ammonia sugar industry and fish oil industry, and expanding the health industry. The "Two Strong and One Large" strategy is a new exploration and practice made under the guidance of the company's "August 8th Strategy", which has achieved phased results in the development of marine biopharmaceuticals and the big health industry.
Sincerely reaching the world and benefiting people's livelihoods. Yan Yiyi said that this is the original intention of Chengyi Pharmaceutical's naming, and it is also one of the winning strategies for enterprises to establish themselves in the market and achieve excellent results over the years. Chengyi Pharmaceutical has been actively rewarding society and the people for many years. According to statistics, since its establishment 57 years ago, the company has paid approximately 720 million yuan in taxes, attracted more than 5000 local people to work in Dongtou, and donated over 20 million yuan in funds and materials. It has been awarded the title of "Meritorious Enterprise for Marine Economic Development" by the Dongtou District Committee and People's Government; Rated as the first batch of "Most Beautiful Factories" in Wenzhou by the Municipal People's Government and awarded the "Mayor's Quality Award" in 2022; Rated by the Provincial Department of Economy and Information Technology as a "Zhejiang Province Cloud Benchmark Enterprise", Chengyi Pharmaceutical is embarking on a path of transformation for private enterprises in Zhejiang, expanding and strengthening, and developing with high quality, from being listed on the market to being listed on the cloud. It is constantly writing about "common prosperity" and "innovation".
Editor: Zhao Shuangyan